All Cellistic articles
-
ArticleEpisode 24 - Genetic engineering for allogeneic immunotherapy
Listen to this podcast where we dive into genetic engineering, its role and relationship with allogeneic immunotherapy.
-
WhitepaperUnder the microscope: Sustaining momentum in iPSC-derived allogeneic cell therapies
Drug Target Review connects with Dr Stefan Braam, co-founder and CTO of Cellistic, and Andy Holt, CCO of Cellistic, for a rundown on today’s landscape for allogeneic cell therapies.